Complement system and rheumatoid arthritis: Relationships with autoantibodies, serological, clinical features, and anti-TNF treatment

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 2, 2011, Pages 357-366

  Di Muzio, G ^a   Perricone, Carlo ^b   Ballanti, E ^a   Kroegler, B ^a   Greco, E ^a   Novelli, L ^a   Conigliaro, P ^a   Cipriani, P ^c   Giacomelli, R ^c   Perricone, R ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Autoantibodies; Complement; Disease activity; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNICARBATE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; COMPLEMENT; COMPLEMENT CH50; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN FRAGMENT; PLASMA PROTEIN; SPLIT PRODUCT OF C3; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOELECTROPHORESIS; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ADULT; ANTIBODY BLOOD LEVEL; COMPLEMENT SYSTEM; CORRELATIONAL STUDY; DAS28; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSPECTIVE STUDY; SEROLOGY; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANALYSIS OF VARIANCE; BLOOD; CHI SQUARE DISTRIBUTION; COMPLEMENT HEMOLYSIS TEST; DRUG ANTAGONISM; HOSPITALIZATION; IMMUNOLOGY; ITALY; METABOLISM; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOELECTROPHORESIS; ITALY; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051751701     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400209     Document Type: Article

References (27)

1. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 2009; 32:158-62.
2. Schellekens GA, De Jong BA, Van den Hoogen FH, Van de Putte LB, Van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-81. (Pubitemid 28058927)
3. Van Venrooij WJ, Zendman AJW, Pruijn GJM. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006; 6:37-41 (Pubitemid 44716772)
4. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30:83-90.
5. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N Engl J Med 2007; 357:1199-209. (Pubitemid 47443179)
6. Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009; 60:1923-31.
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24 (Pubitemid 18091653)
8. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43:1252-5 (Pubitemid 39359299)
9. Van Gestel AM, Prevoo ML, Van 't Hof MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34-40. (Pubitemid 26036375)
10. Perricone C, De Carolis C, Giacomelli R, Greco E, Cipriani P, Ballanti E, Novelli L, Perricone R. Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. Int J Immunopathol Pharmacol 2011; 24:63-8.
11. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51-131.
12. Perricone R, De Carolis C, Giacomello F, Giacomelli R, De Sanctis G, Fontana L. Impaired human ovarian follicular fluid complement function in hereditary angioedema. Scand J Immunol 2000; 51:104-8. (Pubitemid 30074311)
13. Watson WC, Cremer MA, Wooley PH, Townes AS. Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis: evidence of restricted IgG3 subclass expression and activation of complement C5 to C5a. Arthritis Rheum 1986; 29:1316-21 (Pubitemid 17214031)
14. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1531 -7.
15. Mollnes TE, Paus A. Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29:1359-64. (Pubitemid 17214036)
16. Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum 2006; 54:1143-50. (Pubitemid 43672927)
17. Neumann E, Barnum SR, Tarner IH, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 2002; 46:934-45. (Pubitemid 34303805)
18. Aggarwal A, Bhardwaj A, Alam S, Misra R. Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford). 2000; 39:189-92. (Pubitemid 30139354)
19. Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US, Herrmann M. Clearance deficiency - a potential link between infections and autoimmunity. Autoimmun Rev 2008; 8:5-8.
20. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken) 2010; 62:1128-43.
21. Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008; 59:32-41. (Pubitemid 351171876)
22. De Vries MK, Van Eijk IC, Van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009; 61:1484-90.
23. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991; 34:1094-105
24. Sampietro T, Bigazzi F, Dal Pino B, et al. Up regulation of C3, C4, and soluble intercellular adhesion molecule-1 co-expresses with high sensitivity C reactive protein in familial hypoalpha lipoproteinaemia: further evidence of inflammatory activation. Heart 2004; 90:1438-42. (Pubitemid 39626321)
25. Széplaki G, Prohászka Z, Duba J, et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177:383-9. (Pubitemid 39505272)
26. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-16.
27. Perricone C, De Carolis C, Perricone R. Glutathione: a key player in autoimmunity. Autoimmun Rev 2009; 8:697-701.